ERBB2 and breast cancer: Moreover, in HER2-positive BC, DUSP6 inhibition with BCI, its derivative BCI-215, and FTY-720 can overcome resistance to HER2 inhibitors by targeting the HER3 signalling pathway, which is often involved in the development of resistance [155].